Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Replimune Group Inc is a biotechnology business based in the US. Replimune Group shares (REPL) are listed on the NASDAQ and all prices are listed in US Dollars. Replimune Group employs 206 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $15.88 |
|---|---|
| 52-week range | $13.05 - $35.93 |
| 50-day moving average | $19.11 |
| 200-day moving average | $18.96 |
| Wall St. target price | $45.60 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.26 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $15.88 from 2022-09-23
| 1 week (2022-09-20) | -1.55% |
|---|---|
| 1 month (2022-08-26) | -17.16% |
| 3 months (2022-06-27) | -11.38% |
| 6 months (2022-03-25) | -0.69% |
| 1 year (2021-09-27) | -50.84% |
|---|---|
| 2 years (2020-09-25) | -25.66% |
| 3 years (2019-09-27) | 18.51% |
| 5 years (2017-09-23) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -16.35% |
| Return on equity TTM | -29.91% |
| Profit margin | 0% |
| Book value | $8.32 |
| Market capitalisation | $783 million |
TTM: trailing 12 months
We're not expecting Replimune Group to pay a dividend over the next 12 months.
Over the last 12 months, Replimune Group's shares have ranged in value from as little as $13.05 up to $35.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Replimune Group's is 1.9564. This would suggest that Replimune Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Replimune Group, Inc. , a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.